理性对待SARS预防用药  

Rationale of the preventive therapy against SARS

作　　者：刘丽萍[1] 李进[1] 刘西秦[1] 

机构地区：[1]解放军302医院药学部,北京100039

出　　处：《中国新药杂志》2004年第S1期1220-1223,共4页Chinese Journal of New Drugs

基　　金：国家十五863重点项目"临床护理规范和医护人员防护规范研究"(2003AA208317)

摘　　要：目前认为,严重急性呼吸综合征(SARS)是由SARS冠状病毒引起的急性呼吸系统传染病,迄今尚无有效的预防和治疗药物。本文对SARS爆发流行期间市场充斥的大量疗效不确的预防药物进行综述,综合评价其有效性、安全性、经济性,旨在对目前实施的预防SARS反弹工作提供参考。Severe acute respiratory syndrome(SARS)is a recently recognized febrile severe lower respiratory illness that is caused by infection with a novel coronavirus,SARS-associated coronavirus(SARS-CoV).To date,however,no specific medications or preventive tools exist to distinguish with certainty SARS-CoV disease from other respiratory illnesses rapidly enough to inform management decisions after the patient presents to the healthcare system.We investigated a large amount of drugs used in the SARS prevention during the SARS outbreak to evaluate their effectiveness,safety and economy.This means that we can be empowered to initiate effective measures and have a ready access to the medications and knowledge to protect people from potentially contagious diseases,in a 'safety first' approach,and be allowed to initiate the most appropriate infection-control measures immediately-with validation and approval from senior members of staff later.

关 键 词：严重急性呼吸综合征 预防用药物 综合评价 

分 类 号：R511.9[医药卫生—内科学]